United Therapeutics Stock Book Value Per Share
| UTHR Stock | USD 367.36 3.03 0.83% |
United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.
United |
United Therapeutics Company Book Value Per Share Analysis
United Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current United Therapeutics Book Value Per Share | 136.74 X |
Most of United Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of United Therapeutics is about 136 times. This is 8143.71% lower than that of the Biotechnology sector and 155.0% lower than that of the Health Care industry. The book value per share for all United States stocks is 92.92% higher than that of the company.
United Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.United Therapeutics is currently under evaluation in book value per share category among its peers.
United Fundamentals
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.40 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 13.18 B | ||||
| Shares Outstanding | 44.64 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 2.3 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 5.90 X | ||||
| Revenue | 2.33 B | ||||
| Gross Profit | 1.78 B | ||||
| EBITDA | 1.39 B | ||||
| Net Income | 984.8 M | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 136.74 X | ||||
| Cash Flow From Operations | 978 M | ||||
| Short Ratio | 7.51 X | ||||
| Earnings Per Share | 22.76 X | ||||
| Price To Earnings To Growth | 1.56 X | ||||
| Target Price | 382.29 | ||||
| Number Of Employees | 1.17 K | ||||
| Beta | 0.56 | ||||
| Market Capitalization | 16.27 B | ||||
| Total Asset | 7.17 B | ||||
| Retained Earnings | 6.03 B | ||||
| Working Capital | 2.75 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
| Net Asset | 7.17 B |
About United Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against United Stock
| 0.49 | DTIL | Precision BioSciences | PairCorr |
| 0.46 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.45 | DRMA | Dermata Therapeutics | PairCorr |
| 0.44 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.42 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.